Chronic graft-versus-host disease

Research output: Contribution to journalReview articlepeer-review


Chronic graft-versus-host disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors of allogeneic bone marrow transplants. Like acute graft-versus-host disease, it does have a strong antitumor effect. The recent National Institutes of Health sponsored Chronic Graft-versus-Host Disease Consensus Conference has proposed new criteria for diagnosis and staging, pathology, biomarkers, response and supportive care. New understanding of the pathophysiology of chronic graft-versus-host disease (i.e. the role of B cells) is already having an impact on therapy. Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic graft-versus-host disease.

Original languageEnglish (US)
Pages (from-to)1974-1986
Number of pages13
JournalCurrent pharmaceutical design
Issue number20
StatePublished - Jul 2008


  • Antitumor effect
  • Chronic graft
  • Extracorporeal photochemotherapy
  • Host Disease
  • Mycophenolate mofetil
  • Novel agents
  • Pathology
  • Pentostatin
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this